

Key factors influencing the Japanese pharma market

Key stats:

 \odot_{\oslash}

() |||| +3.3%/\$48.81bn

The estimated Japanese pharma market revenue in 2025

Japan's pharmaceutical industry remains one of the largest globally,

holding around 5% of the market share

Medicine sales to reach **\$58.40bn by 2029** experiencing a 5-year CAGR of 4.3%

Strengths:

- Asia-Pacific's largest pharmaceutical market, offering unparalleled business opportunities.
- High pharmaceutical spending per capita, demonstrating a strong demand for advanced healthcare solutions.
- A well-established intellectual property framework that encourages innovation.
- Thriving patented drugs market driven by innovation and a growing need for specialised treatments.
- World-class pharmaceutical manufacturing hub, boasting state-of-the-art production facilities and a high level of investment in research and development.
- Rapidly evolving clinical research landscape, supported by cutting-edge infrastructure and increased collaboration between industry and academia.
- A rapidly aging population, creating a rising demand for healthcare services, pharmaceuticals, and long-term care solutions.
- A highly developed healthcare infrastructure, backed by strong government economic support.

Source:

Fitch Solutions, Japan Pharmaceuticals Report Q4 2024 & Pharmaceuticals - Japan | Statista Market Forecast

Strengths:

- The underdeveloped generic drug market is poised for growth, fuelled by government incentives, ongoing drug shortages, and the expiration of key patents, presenting significant opportunities for expansion.
- Recent updates to regulations and the acceleration of approval processes for innovative drugs are creating enhanced opportunities for multinational companies to introduce new products and expand their market presence.
- Increasing partnerships between domestic and international manufacturers are expected to accelerate sales growth and strengthen marketing reach across the market.
- An aging population coupled with a growing prevalence of chronic and long-term diseases continues to create sustained demand for innovative healthcare solutions, offering substantial opportunities for product developers.

Challenges



50

Increasing competition from emerging regional companies is shaping the market dynamics, requiring businesses to adopt innovative strategies to maintain a competitive edge

Ongoing government cost-reduction measures are influencing market pricing structures and driving the need for operational efficiency across the sector



For more **information on the Japanese pharma market** and to learn about opportunities at CPHI Japan please visit:

cphi.com/japan